Summary

The global Non-Tyrosine Kinase Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Non-Tyrosine Kinase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Non-Tyrosine Kinase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Non-Tyrosine Kinase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Non-Tyrosine Kinase Inhibitors players cover Roche, Eli Lilly, Novartis, Array BioPharma, Nerviano Medical Sciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Non-Tyrosine Kinase Inhibitors Industry Forecast” looks at past sales and reviews total world Non-Tyrosine Kinase Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-Tyrosine Kinase Inhibitors sales for 2025 through 2031. With Non-Tyrosine Kinase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Tyrosine Kinase Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Non-Tyrosine Kinase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-Tyrosine Kinase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Tyrosine Kinase Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Tyrosine Kinase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Tyrosine Kinase Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Tyrosine Kinase Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Segmentation by Application:
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Non-Tyrosine Kinase Inhibitors market?
What factors are driving Non-Tyrosine Kinase Inhibitors market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Non-Tyrosine Kinase Inhibitors market opportunities vary by end market size?
How does Non-Tyrosine Kinase Inhibitors break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Non-Tyrosine Kinase Inhibitors by Country/Region, 2020, 2024 & 2031
2.2 Non-Tyrosine Kinase Inhibitors Segment by Type
2.2.1 mTOR Inhibitors
2.2.2 RAF/MEK Inhibitors
2.2.3 CDK Inhibitors
2.3 Non-Tyrosine Kinase Inhibitors Sales by Type
2.3.1 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Type (2020-2025)
2.3.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Type (2020-2025)
2.3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Type (2020-2025)
2.4 Non-Tyrosine Kinase Inhibitors Segment by Application
2.4.1 Liver Cancer
2.4.2 Respiratory Cancer
2.4.3 Brain Cancer
2.4.4 Others
2.5 Non-Tyrosine Kinase Inhibitors Sales by Application
2.5.1 Global Non-Tyrosine Kinase Inhibitors Sale Market Share by Application (2020-2025)
2.5.2 Global Non-Tyrosine Kinase Inhibitors Revenue and Market Share by Application (2020-2025)
2.5.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Non-Tyrosine Kinase Inhibitors Breakdown Data by Company
3.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Company (2020-2025)
3.1.2 Global Non-Tyrosine Kinase Inhibitors Sales Market Share by Company (2020-2025)
3.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Company (2020-2025)
3.2.1 Global Non-Tyrosine Kinase Inhibitors Revenue by Company (2020-2025)
3.2.2 Global Non-Tyrosine Kinase Inhibitors Revenue Market Share by Company (2020-2025)
3.3 Global Non-Tyrosine Kinase Inhibitors Sale Price by Company
3.4 Key Manufacturers Non-Tyrosine Kinase Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Non-Tyrosine Kinase Inhibitors Product Location Distribution
3.4.2 Players Non-Tyrosine Kinase Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Non-Tyrosine Kinase Inhibitors by Geographic Region
4.1 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Geographic Region (2020-2025)
4.1.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Non-Tyrosine Kinase Inhibitors Market Size by Country/Region (2020-2025)
4.2.1 Global Non-Tyrosine Kinase Inhibitors Annual Sales by Country/Region (2020-2025)
4.2.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-Tyrosine Kinase Inhibitors Sales Growth
4.4 APAC Non-Tyrosine Kinase Inhibitors Sales Growth
4.5 Europe Non-Tyrosine Kinase Inhibitors Sales Growth
4.6 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales Growth
5 Americas
5.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country
5.1.1 Americas Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025)
5.1.2 Americas Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025)
5.2 Americas Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025)
5.3 Americas Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region
6.1.1 APAC Non-Tyrosine Kinase Inhibitors Sales by Region (2020-2025)
6.1.2 APAC Non-Tyrosine Kinase Inhibitors Revenue by Region (2020-2025)
6.2 APAC Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025)
6.3 APAC Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Non-Tyrosine Kinase Inhibitors by Country
7.1.1 Europe Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025)
7.1.2 Europe Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025)
7.2 Europe Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025)
7.3 Europe Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors by Country
8.1.1 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Country (2020-2025)
8.1.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Revenue by Country (2020-2025)
8.2 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Type (2020-2025)
8.3 Middle East & Africa Non-Tyrosine Kinase Inhibitors Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Non-Tyrosine Kinase Inhibitors
10.3 Manufacturing Process Analysis of Non-Tyrosine Kinase Inhibitors
10.4 Industry Chain Structure of Non-Tyrosine Kinase Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Non-Tyrosine Kinase Inhibitors Distributors
11.3 Non-Tyrosine Kinase Inhibitors Customer
12 World Forecast Review for Non-Tyrosine Kinase Inhibitors by Geographic Region
12.1 Global Non-Tyrosine Kinase Inhibitors Market Size Forecast by Region
12.1.1 Global Non-Tyrosine Kinase Inhibitors Forecast by Region (2026-2031)
12.1.2 Global Non-Tyrosine Kinase Inhibitors Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Non-Tyrosine Kinase Inhibitors Forecast by Type (2026-2031)
12.7 Global Non-Tyrosine Kinase Inhibitors Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Eli Lilly
13.2.1 Eli Lilly Company Information
13.2.2 Eli Lilly Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Eli Lilly Main Business Overview
13.2.5 Eli Lilly Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Array BioPharma
13.4.1 Array BioPharma Company Information
13.4.2 Array BioPharma Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Array BioPharma Main Business Overview
13.4.5 Array BioPharma Latest Developments
13.5 Nerviano Medical Sciences
13.5.1 Nerviano Medical Sciences Company Information
13.5.2 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Nerviano Medical Sciences Main Business Overview
13.5.5 Nerviano Medical Sciences Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Merck KGaA
13.7.1 Merck KGaA Company Information
13.7.2 Merck KGaA Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Merck KGaA Main Business Overview
13.7.5 Merck KGaA Latest Developments
13.8 Astex Pharmaceuticals
13.8.1 Astex Pharmaceuticals Company Information
13.8.2 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Astex Pharmaceuticals Main Business Overview
13.8.5 Astex Pharmaceuticals Latest Developments
13.9 Cyclacel Pharmaceuticals
13.9.1 Cyclacel Pharmaceuticals Company Information
13.9.2 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Cyclacel Pharmaceuticals Main Business Overview
13.9.5 Cyclacel Pharmaceuticals Latest Developments
13.10 Daiichi Sankyo
13.10.1 Daiichi Sankyo Company Information
13.10.2 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Daiichi Sankyo Main Business Overview
13.10.5 Daiichi Sankyo Latest Developments
13.11 Onconova Therapeutics
13.11.1 Onconova Therapeutics Company Information
13.11.2 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Onconova Therapeutics Main Business Overview
13.11.5 Onconova Therapeutics Latest Developments
13.12 AstraZeneca
13.12.1 AstraZeneca Company Information
13.12.2 AstraZeneca Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 AstraZeneca Main Business Overview
13.12.5 AstraZeneca Latest Developments
13.13 GlaxoSmithKline (GSK)
13.13.1 GlaxoSmithKline (GSK) Company Information
13.13.2 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 GlaxoSmithKline (GSK) Main Business Overview
13.13.5 GlaxoSmithKline (GSK) Latest Developments
13.14 Carna Biosciences
13.14.1 Carna Biosciences Company Information
13.14.2 Carna Biosciences Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Carna Biosciences Main Business Overview
13.14.5 Carna Biosciences Latest Developments
13.15 Celgene Corporation
13.15.1 Celgene Corporation Company Information
13.15.2 Celgene Corporation Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Celgene Corporation Main Business Overview
13.15.5 Celgene Corporation Latest Developments
13.16 Eternity Bioscience
13.16.1 Eternity Bioscience Company Information
13.16.2 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Eternity Bioscience Main Business Overview
13.16.5 Eternity Bioscience Latest Developments
13.17 Jasco Pharmaceuticals
13.17.1 Jasco Pharmaceuticals Company Information
13.17.2 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Product Portfolios and Specifications
13.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Jasco Pharmaceuticals Main Business Overview
13.17.5 Jasco Pharmaceuticals Latest Developments
14 Research Findings and Conclusion